Inovio pharmaceuticals, inc. (INO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-124,398

-120,551

-115,366

-116,845

-93,905

-96,967

-85,511

-94,630

-97,470

-88,205

-92,933

-79,557

-88,783

-73,740

-65,458

-39,105

-26,562

-29,102

-18,563

-31,336

-35,892

-36,140

-44,195

-67,907

-68,056

-66,083

-51,287

-27,028

-20,306

-19,712

-24,529

-22,453

-21,146

-15,304

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

3,477

3,598

3,725

3,769

3,780

3,747

2,838

2,670

2,225

1,850

2,195

1,901

1,842

1,708

1,607

1,424

1,222

1,048

931

833

725

626

633

491

404

328

174

177

176

173

164

152

146

142

0

0

0

Amortization of Intangible Assets

936

1,066

1,066

1,066

1,112

1,249

1,387

1,524

1,616

1,618

1,623

1,631

1,574

1,377

1,181

984

856

870

888

907

926

942

1,149

1,354

1,562

1,770

1,783

1,796

1,808

1,821

1,833

1,846

1,858

1,869

0

0

0

Amortization of operating lease right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of common stock warrants

-

-

-

-

-

-360

-940

-1,134

-562

-806

-872

-451

-653

-127

807

291

230

-177

-611

21

-852

-348

5,848

40,686

44,710

45,632

36,530

2,691

-4,103

-1,982

-46

-1,506

-2,810

-8,690

0

0

0

Change in fair value of derivative liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

11,470

10,901

11,006

11,277

10,511

10,654

11,193

11,298

11,273

13,070

13,488

13,165

12,794

10,479

8,670

7,664

6,832

6,186

5,781

5,449

5,321

5,428

5,078

4,827

3,868

1,868

1,507

1,261

1,261

1,345

1,399

1,382

1,276

1,654

0

0

0

Non-cash interest expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest Expense

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Transaction costs associated with issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

315

315

315

315

0

0

0

0

-

-

-

-

Amortization of premiums on investments

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-0

-0

-2

-1

0

0

0

-

-

-

0

Loss on short-term investments

36

476

-546

-874

-1,124

-1,342

-695

-521

-417

-215

0

0

0

-

0

0

0

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Settlement of receivable with shares of common stock from affiliated entity (PLS)

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-4

-4

-4

-1

0

0

0

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in Value of Investments in Affiliated Company

10,841

-3,090

-4,702

-3,199

-5,119

-1,988

1,597

-5,255

-2,993

-6,982

-11,981

-7,104

-7,979

1,110

2,567

2,867

12,433

2,600

9,192

11,020

700

2,676

-2,085

-5

-579

-1,038

2,830

317

1,357

1,631

-1,658

-967

-2,582

-2,390

0

0

0

Transaction costs associated with issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Gain on sale of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,151

1,151

988

988

587

0

0

0

Tax benefit from other unrealized gains on short-term investments

-48

-266

-335

-335

-217

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized transaction loss on foreign-currency denominated debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-2,141

-2,616

-2,055

-1,582

-2,364

-2,686

-3,405

-5,809

-4,717

-9,818

-11,184

-2,809

-1,254

8,521

6,458

4,725

7,821

4,497

9,341

2,730

598

-499

-8,988

2,300

1,634

2,434

10,092

108

152

362

54

84

732

435

0

0

0

Accounts receivable from affiliated entities

-661

593

-589

36

-946

251

642

-228

1,009

-261

891

1,155

1,199

714

0

0

0

-

-

-

-

-

-

-

0

-

-134

-33

4

-2

106

-56

13

-33

0

0

0

Prepaid expenses and other current assets

1,092

178

75

524

-615

-1,194

-2,936

-3,129

-2,204

851

3,147

3,726

3,083

831

42

636

465

119

763

-166

149

160

113

7

288

229

-41

86

-566

-363

-378

-223

415

472

0

0

0

Prepaid expenses and other current assets from affiliated entities

349

-70

-526

-686

-233

-725

1,109

535

-141

333

-700

-630

278

901

1,062

836

-478

-771

-954

524

244

-674

1,247

-11

1,171

1,401

-113

-50

431

445

340

-178

-720

-212

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

-

-

-

-

Other assets

-501

2

105

128

532

30

428

1,050

923

526

715

348

493

1,442

884

744

366

196

195

179

263

72

0

-25

-26

-26

-26

-0

30

14

14

14

-62

-50

0

0

0

Accounts payable and accrued expenses

-4,556

-4,337

-7,352

807

-84

550

-3,178

-2,309

2,109

2,829

4,538

2,309

2,346

6,367

7,014

6,714

6,821

6,456

4,287

396

-1,134

925

360

1,667

2,017

2,123

861

385

676

-790

415

1,013

982

1,789

0

0

0

Accrued clinical trial expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued clinical trial expenses

-

-

-

-

-

-

0

0

2,519

-

703

2,182

1,759

3,767

4,273

2,459

2,883

593

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses due to affiliated entities

-1,052

-248

-228

52

16

50

-91

-246

769

-145

289

246

321

907

-2,319

-2,816

202

136

2,718

2,712

-774

-493

-400

659

401

334

384

-8

295

166

-496

-703

-587

-1,660

0

0

0

Deferred revenue

-84

-180

-154

-700

-24,039

-1,016

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

2,314

-

2,208

14,410

14,450

10,191

9,833

-2,628

-3,246

-260

1,361

2,918

3,480

3,179

1,617

55

161

282

20

-180

-205

-333

0

0

0

Deferred revenue from affiliated entities

-1

-1

-3

40

-53

-140

-175

-219

-312

-319

-375

-469

-375

-687

-702

-337

-375

-49

-22

-375

-374

-368

-362

-356

-375

-375

-375

-375

-375

-375

-375

-375

-373

-361

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

-

-3,608

-2,362

-1,884

-1,181

16

59

-110

-269

-383

-491

-628

-742

-762

-699

-249

-561

-410

-295

-525

22

15

0

0

0

-

-

-

-

Operating lease right-of-use assets and liabilities, net

-2,115

-1,733

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant funding liability

11,812

1,899

599

-150

1,279

4,165

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant funding liability from affiliated entities

779

816

816

655

14

27

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

11

-48

-47

52

-197

87

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-90,848

-97,850

-101,393

-98,331

-93,429

-73,550

-70,217

-62,860

-60,556

-63,208

-64,163

-65,492

-62,042

-62,555

-54,426

-20,358

-16,110

-12,438

-13,739

-37,207

-36,334

-29,823

-20,874

-18,535

-15,808

-15,381

-21,778

-22,107

-21,999

-22,306

-21,318

-20,551

-19,690

-19,755

0

0

0

Cash flows from investing activities:
Purchases of investments

92,450

100,950

127,236

130,534

143,785

88,155

61,300

112,419

99,342

95,700

97,091

43,932

51,079

57,317

68,630

56,318

70,700

63,526

65,289

74,092

46,175

47,185

28,995

17,994

20,999

15,399

7,191

8,515

6,433

9,142

20,067

18,746

17,636

18,193

0

0

0

Proceeds from sale or maturity of investments

81,403

92,893

116,155

125,595

111,654

132,659

112,739

98,742

89,806

77,162

74,079

81,038

88,904

76,528

57,460

34,401

19,804

10,484

9,597

9,598

9,039

12,753

11,789

10,789

10,789

4,339

4,450

8,734

12,188

14,008

15,374

11,091

7,637

7,206

0

0

0

Purchases of capital assets

470

987

1,216

1,210

1,590

2,085

2,620

6,080

10,658

10,293

9,482

6,369

2,846

2,738

3,498

3,805

2,935

2,781

2,127

1,665

1,725

1,379

1,134

997

318

176

271

104

184

240

267

268

197

161

0

0

0

Proceeds from sale of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

650

0

0

0

-

-

-

-

Proceeds from sale of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in investing activities

-11,516

-9,044

-12,297

-6,148

-33,721

42,419

49,818

-18,756

-19,195

-27,831

-32,494

30,736

34,777

16,271

-14,868

-25,922

-52,832

-54,824

-56,819

-65,160

-38,860

-35,812

-17,340

-7,203

-8,529

-9,236

-2,013

1,614

6,070

5,275

-4,310

-7,774

-10,048

-10,899

0

0

0

Cash flows from financing activities:
Proceeds from issuance of convertible senior notes

21,784

97,443

93,425

75,658

75,658

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

216,423

9,089

17,729

29,550

30,135

29,227

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

59,209

63,015

72,536

72,536

32,883

33,177

24,881

24,881

5,325

4,910

3,685

3,685

27,994

0

0

0

Proceeds from stock option exercises

0

-

-

-

0

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Taxes paid related to net share settlement of equity awards

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of non-controlling interest

2,100

2,960

3,016

3,016

3,030

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

240,033

105,397

110,146

109,130

110,420

31,037

16,518

72,842

94,357

95,690

96,685

30,165

8,543

7,786

7,076

4,433

84,421

84,351

85,358

84,130

2,570

72,461

75,817

103,921

103,021

52,691

52,269

24,892

24,886

5,325

4,913

3,688

3,688

28,010

0

0

0

Increase (Decrease) in cash and cash equivalents

137,667

-1,497

-3,544

4,650

-16,729

-92

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-1

0

-0

0

0

0

0

1

1

-3

-2

-3

0

0

0

Increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

27

-4,589

-18,720

-38,496

-62,218

-41,847

15,478

17,088

14,799

-18,237

-72,625

6,824

37,601

78,183

78,684

28,073

28,478

4,400

8,957

-11,704

-20,714

-24,642

-26,053

-2,648

0

0

0

Supplemental disclosure:
Amounts accrued for purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

835

225

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosures:
Amounts accrued for purchases of property and equipment

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for lease obligations

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-